Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1

Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: bai J

Authors: Bai J, Tang Q,

Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,

#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Beek D

Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,

Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,

#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hackeng W, Geisenberger C, de Leng W, Morsink F, Vriens M,

Keywords: Methylation profiling, Neuroendocrine tumor, Machine Learning, Unknown Primary,

#2285 The Role of Magnetic Resonance Imaging and Endoscopic Ultrasound Imaging in the Diagnosis and Management of Pancreatic Neuroendocrine Tumors (pNET) in Patients with Multiple Endocrine Neoplasia Type 1 (MEN1)

Introduction: Pancreatic neuroendocrine tumors (pNETs) in patients with Multiple Endocrine Neoplasia Syndrome type 1 (MEN 1) are frequently multiple and occur with an incidence that varies from 30-80% in different series. Magnetic Resonance Imaging (MRI) and techniques such as endoscopic ultrasound (EUS) are useful tools for tumor localization, size assessment and follow-up.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Tsoli M, Alexandraki K, Angelousi A, Karoumpalis I, Kolomodi D,

Keywords: pancreatic, neuroendocrine, MEN1, MRI, EUS,

#2176 New MENIN Mutation Associated with Familial Isolated Hyperparathyroidism. Clinical Case of Three Young Sisters.

Introduction: The primary hyperparathyroidism (PHPT) is a sporadic disorder in the majority of cases, and only 5-10% of cases are associated with familial syndromes. The following familial syndromes associated with PHPT are known to date: multiple endocrine neoplasia type 1 (MEN1), type 2A (MEN2A), type 4 (MEN4), hyperparathyroidism-jaw tumor syndrome (HPT-JT), familial hypocalciuric hypercalcemia (FHH), neonatal severe hyperparathyroidism (NSHPT) and familial isolated hyperparathyroidism (FIHP). FIHP is defined as hereditary PHPT without the association with other diseases or tumors and may be caused by mutations in MEN1, HRPT2, or CASR genes.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Krupinova K

Authors: Mokrysheva N, Krupinova J, Eremkina A, Tiulpakov A,

Keywords: primary hyperparathyroidism, familial isolated hyperparathyroidism, familial syndromes, MEN1, parathyroid hyperplasia,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.